Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

about

Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.

P2860

Q47669469-4C04E7DE-DD81-48B1-A12C-0C6ACB5E46AB

P2860

Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

Item

http://www.wikidata.org/entity/Q39794883

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@en

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@nl

type

Item

label

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@en

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@nl

prefLabel

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@en

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@nl

P1476

Model-based evaluation of pulm ...... er oral olodaterol inhalation.

@en

P2093

Alexander Staab

http://www.w3.org/2001/XMLSchema#string

Benjamin Weber

http://www.w3.org/2001/XMLSchema#string

Charlotte Kloft

http://www.w3.org/2001/XMLSchema#string

Christina Kunz

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Prediction of creatinine clearance from serum creatinine

Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects.

Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling.

Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.

The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease

Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.

Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics.

Differences in airway remodeling between asthma and chronic obstructive pulmonary disease.

Aerosol deposition in health and disease

P304

739-753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12999

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jens Markus Borghardt

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27145733

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

asthma

P932

5338120

http://www.w3.org/2001/XMLSchema#string

Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

about

P2860

P2860

Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932